Parthenogenetic ESCs have defended their rights
In Europe, it was allowed to obtain patents for the results of research on embryonic stem cells
We are talking about studies of cells obtained by parthenogenetic activation (without fertilization) of oocytes, writes Reuters (UPDATE 2-EU's top court opens door to some stem cell patents).
For a long time, there has been a debate about the ethics of human embryonic stem cells. Critics argued that the use and destruction of human embryos is unacceptable. At the same time, many researchers believe that therapy based on such cells will help in the fight against a number of serious diseases, including Parkinson's disease.
After considering the case of the company International Stem Cell, which wants to obtain a patent for its research, the European Court ruled in 2011 that the results of work on human embryonic stem cells cannot be patented. Now the court has recognized that the division of an egg after parthenogenetic activation cannot be considered the development of a human embryo. As a result, International Stem Cell, which uses similar technologies in its work, received the right to their patent.
Parthenogenetic lines of "non-embryonic" human stem cells will be completely histocompatible
with the body of an oocyte donor or recipient with matching proteins
the main histocompatibility complex (HLA).
Fig. from the website internationalstemcell.com – VM.
Parthenogenetic activation of mammalian oocytes can be used as an alternative for fertilization with sperm for the preparation of oocytes in order to obtain embryonic stem cells. In parthenogenetic activation, only female gametes are used.
Portal "Eternal youth" http://vechnayamolodost.ru22.12.2014